Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Featured Story 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is a requirement. Most, if not all, of these companies are still in the clinical stage, meaning they have no commercially available drugs or therapeutics. It also means these companies have negative earnings (i.e., are not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. A major shift is coming to the gold market — the world's largest gold buyer is preparing to launch a new way for everyday Americans to invest in gold with a click, and when it goes live in 2026 it could unleash a wave of demand unlike anything we've seen. Garrett Goggin believes one $1.60 gold stock is positioned to be a prime beneficiary of this surge — a move where even a small price jump could mean a meaningful gain — along with several other miners set to ride the same trend. Click here to see the $1.60 gold stock and Garrett's full list of recommendations Even if a product advances through trials, profitability may still be years away. Only after reaching that milestone do they typically receive analyst coverage and attract institutional investors. However, getting in on one of these medical stocks and having it hit can be transformative. In an instant, investors could see 3x, 5x, or even 10x returns. Others may never pan out. That’s why many investors interested in penny stocks spread a lump sum across numerous biotech names. If it is indeed a numbers game, diversification can be an effective strategy. With that in mind, let's examine two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company specializing in epigenetics-based tests for the early detection of cancer. Unlike some penny stocks in this space, Mainz Biomed has a commercially available product: ColoAlert–the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s leading digital health pioneers. With over 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. Mainz Biomed is also developing a non-invasive blood-based screening test for the early detection of pancreatic cancer and reported positive topline results in October. That program, however, is still years away from potential commercial approval. That said, the risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains minimal. That's why the company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed filed a $150 million mixed shelf offering. For now, that appears sufficient to keep the MYNZ stock price above $1 and avoid a delisting notice. The company is racing to generate enough revenue to move the needle. If it succeeds, even a small investment could deliver a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech offering a potentially disruptive approach to antiviral treatment—but it also carries the financial risk that speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. If validated in human trials, this approach could represent a novel method for treating infectious diseases. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced, with encouraging preclinical data suggesting strong antiviral activity. But like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to keep programs moving. The company reported limited cash on hand in recent filings, and investors should expect the possibility of future dilution. Still, if one of its candidates advances into clinical development and proves successful, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC stock represents a genuine moonshot in the antiviral space. Both Mainz Biomed and NanoViricides illustrate the trade-off in small-cap biotech investing: limited revenue and significant dilution risk, counterbalanced by the potential for asymmetric returns if development programs succeed. These names may appeal to investors who can accept high volatility and the possibility of total loss in pursuit of outsized gains.
| 
